SCHEMBL10133136

SCHEMBL10133136

CCCCCCCCCCCCCCCCCCOC[C@H](C)OCCCCCCCCCCCCCCCCCC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.52
LPAR1 Q92633 7/20 0.50
LPAR3 Q9UBY5 7/20 0.50
LPAR2 Q9HBW0 4/20 0.50
HTT P42858 2/20 0.50
SPHK1 Q9NYA1 1/20 0.50
TDP1 Q9NUW8 1/20 0.48
DNM1 Q05193 1/20 0.45
PRKD3 O94806 1/20 0.44
PRKCG P05129 1/20 0.44
PRKCB P05771 1/20 0.44
PRKCA P17252 1/20 0.44
PRKCH P24723 1/20 0.44
PRKCI P41743 1/20 0.44
PRKCE Q02156 1/20 0.44
PRKCQ Q04759 1/20 0.44
PRKCZ Q05513 1/20 0.44
PRKCD Q05655 1/20 0.44
PRKD1 Q15139 1/20 0.44
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1932689 1.00 USP2 (0.52) USP2LPAR1LPAR3LPAR2HTT
SCHEMBL13966877 1.00 USP2 (0.52) USP2LPAR1LPAR3LPAR2HTT
SCHEMBL8641219 1.00 USP2 (0.52) USP2LPAR1LPAR3LPAR2HTT
SCHEMBL16338301 1.00 USP2 (0.52) USP2LPAR1LPAR3LPAR2HTT
SCHEMBL8644294 1.00 USP2 (0.52) USP2LPAR1LPAR3LPAR2HTT
SCHEMBL8646854 1.00 USP2 (0.52) USP2LPAR1LPAR3LPAR2HTT
SCHEMBL10133129 1.00 USP2 (0.52) USP2LPAR1LPAR3LPAR2HTT
SCHEMBL2979667 1.00 USP2 (0.52) USP2LPAR1LPAR3LPAR2HTT
SCHEMBL13966880 1.00 USP2 (0.52) USP2LPAR1LPAR3LPAR2HTT
Ammonia Solution, Strong SCHEMBL16798365 0.98 USP2 (0.50) USP2LPAR1LPAR3LPAR2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8802644-B2 Lipid formulation TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2014-08-12 US disclosed
US-8802644-B2 Lipid formulation TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2014-08-12 US disclosed
US-20130202652-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS ALNYLAM PHARMACEUTICALS, INC. (US) 2013-08-08 US disclosed
US-20130202652-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS ALNYLAM PHARMACEUTICALS, INC. (US) 2013-08-08 US disclosed
US-8158601-B2 Lipid formulation ALNYLAM PHARMACEUTICALS, INC. (US) 2012-04-17 US disclosed
US-8158601-B2 Lipid formulation ALNYLAM PHARMACEUTICALS, INC. (US) 2012-04-17 US disclosed
US-20100324120-A1 LIPID FORMULATION BANK OF AMERICA, N.A. 2010-12-23 US disclosed
US-20100324120-A1 LIPID FORMULATION BANK OF AMERICA, N.A. 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324120-A1 LIPID FORMULATION CETP, LIPA, SGMS1 USP2 3816/4885LPAR1 91/4885LPAR3 107/4885
US-20130202652-A1 METHODS AND COMPOSITIONS FOR DELIVERY OF ACTIVE AGENTS FUCA1, FUCA2, ANXA2 USP2 4074/4885LPAR1 178/4885LPAR3 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.